Phospho-MYBL2 (S577) Antibody

1. Research findings suggest that B-Myb-A3B contributes to DNA damage and could be targeted by inhibiting EGF receptor. PMID: 28276478
2. Structural and biochemical analyses provide insight into how oncogenic B-Myb is recruited to regulate genes required for cell-cycle progression. The MMB interface presents a potential therapeutic target to inhibit cancer cell proliferation. PMID: 30224471
3. B-Myb is an independent prognostic marker and a potential target in the diagnosis and/or treatment of NSCLC. It functions as a tumor-promoting gene by targeting IGFBP3 in NSCLC cells. PMID: 29772705
4. MYBL2 is a key downstream factor of Akt/FoxM1 signaling that promotes the progression of human glioma. It could be a new candidate gene for molecular targeting therapy and biomarker for glioma radiotherapy. PMID: 28784180
5. These results suggested that overexpression of MYBL2 might serve as a novel prognostic biomarker in pancreatic ductal adenocarcinoma patients. PMID: 28559119
6. A total of 41 differentially expressed genes, such as SOCS3, VAPA, and COL5A2, are speculated to have roles in the pathogenesis of acute myocardial infarction. Two transcription factors, FOXO3 and MYBL2, and two miRNAs, hsa-miR-21-5p and hsa-miR-30c-5p, may be involved in the regulation of the expression of these differentially expressed genes. PMID: 29049183
7. Research indicates that the oncogenic transcription factor HIF-2alpha stabilizes the VHL disease suppressor B-Myb, which is also a transcription factor, through physical interaction. Some B-Myb-dependent gene expression was similarly affected by B-Myb or HIF-2alpha knockdown, suggesting that stabilization of B-Myb by HIF-2alpha may play a role in specific gene expressions. PMID: 28394947
8. The MuvB multiprotein complex, together with B-MYB and FOXM1 (MMB-FOXM1), regulates the expression of mitotic kinesins in breast cancer cells. PMID: 28061449
9. MYBL2 overexpression promotes Gallbladder Cancer cell proliferation through the regulation of the cell cycle at the S and G2/M phase transitions. Thus, MYBL2 could serve as a potential prognostic and therapeutic biomarker in Gallbladder Cancer patients. PMID: 28427077
10. A study identified B-Myb as a substrate of the pVHL ubiquitin ligase complex, which targets it for degradation via the ubiquitin-proteasome pathway. It also provides evidence that the regulation of B-Myb by pVHL plays a critical role in von Hippel-Lindau disease. PMID: 27090638
11. Data indicate that gene expression alterations in endometrial carcinoma samples with high ATAD2 expression showed upregulation of several cancer-related genes including the B-MYB gene. PMID: 26308378
12. We found that B-Myb upregulated expression of the key epithelial-to-mesenchymal transition regulator snail, mediating epithelial-to-mesenchymal transition activation and cell invasion by B-Myb. PMID: 25502082
13. The study concludes that downregulation of MYBL2 activity below levels predicted by classical haploinsufficiency underlies the clonal expansion of hematopoietic progenitors in a large fraction of human myeloid malignancies. PMID: 23878725
14. B-Myb plays a role in the suppression of keratinocyte differentiation and maintenance of the undifferentiated proliferative phenotype by modulating the expression levels of cell cycle regulatory proteins, expressed in the S and G2/M phases of the cell cycle. PMID: 24515894
15. Results show that E7 interacts with the B-Myb, FoxM1, and LIN9 components of this activator complex, leading to cooperative transcriptional activation of mitotic genes in primary cells and E7 recruitment to the corresponding promoters. PMID: 24141769
16. MYBL2 expression analysis could be useful to define subgroups of patients with poor prognosis. PMID: 24199710
17. MALAT1-depleted cells display reduced expression of B-MYB (Mybl2), an oncogenic transcription factor involved in G2/M progression, due to altered binding of splicing factors on B-MYB pre-mRNA and aberrant alternative splicing. PMID: 23555285
18. Low MYBL2 expression is associated with hematopoietic neoplasia. PMID: 22910183
19. A novel role for B-Myb in S-phase that appears to be independent of its sequence-specific DNA-binding activity and its ability to stimulate the expression of bona fide B-Myb target genes. PMID: 23032261
20. Mybl2 upregulation induces fast growth and progression of premalignant and malignant liver, through cell cycle deregulation and activation of genes and pathways related to tumor progression. PMID: 21419759
21. Owing to the role of B-Myb and E2F1 transcription factors in controlling cell-cycle progression of leukemic cells, the downregulation of these oncogenes by miR-34a suggests the usefulness of therapeutic approaches aimed to modulate the levels of miR-34a. PMID: 21367750
22. The study concludes that MYCN and B-MYB are engaged in a reciprocal regulatory loop whose pharmacological targeting could be beneficial to patients with the aggressive forms of cancer in which MYCN is amplified. PMID: 21304178
23. MYBL2 activation is crucial for human HCC progression. In particular, our data indicate that MYBL2-LIN9 complex integrity contributes to the survival of DNA-damaged p53(-/-) cells. PMID: 21480327
24. B-MYB acts as a positive regulator of STRAP. PMID: 21148321
25. B-MYB represses p16(INK4alpha) by binding to a MYB-binding site within the promoter region. PMID: 20734103
26. miR-29 and miR-30 regulate B-Myb expression by binding to its 3'UTR; these microRNAs play an important role in Rb-driven cellular senescence. PMID: 21187425
27. Data show that ANCCA is crucial for the proliferation and survival of triple-negative/basal-like cancer cells and that it controls the expression of B-Myb and histone methyltransferase EZH2. PMID: 20864510
28. These data suggest that Mybl2 plays a subtle but key role in linking specific aspects of cell-cycle progression with the generation of signals for differentiation. PMID: 20857481
29. A study identified an overrepresentation of focal amplifications of known (FGFR3, CCND1, MYC, MDM2) and novel candidate genes (MYBL2, YWHAB, and SDC4) in stage Ta bladder carcinoma. PMID: 19821490
30. B-Myb transactivates the IGFBP-5 promoter. PMID: 11973331
31. ZPR9 plays an important role in the modulation of the transactivation by B-MYB and cellular growth of neuroblastoma cells. PMID: 12645566
32. B-Myb repressor function is regulated by cyclin A phosphorylation and sequences within the C-terminal domain. PMID: 12673206
33. It is evident that B-Myb protein may promote cell proliferation by a non-transcriptional mechanism that involves the release of active cyclin/cyclin-dependent kinase 2 from cyclin-dependent inhibitor 1C p57(KIP2). PMID: 12947099
34. MRGX can repress or activate the B-myb promoter depending on the cell type studied, suggesting that there may be tissue-specific functions of this protein. PMID: 14506250
35. B-Myb has a role in the regulation of c-Myc expression by cytosolic phospholipase A2. PMID: 14769798
36. Human B-Myb reduces neointima formation after vascular injury in transgenic mice. PMID: 15256398
37. B-Myb is regulated by temperature to activate genes required for cell survival. PMID: 15618219
38. B-Myb is overexpressed during the S phase of the cell cycle compared with the G0/1 phase. PMID: 16476973
39. Chromosomal fragmentation and other aberrations, including shorter, thicker chromatids, end-to-end fusion, and loss of a chromatid, suggest that reduced B-Myb activity is also associated with structural chromosomal instability. PMID: 16551698
40. Mip/LIN-9 is required for the expression of B-Myb, and both proteins collaborate in the control of the cell cycle progression via the regulation of S phase and cyclin A, cyclin B, and CDK1. PMID: 17098733
41. Human LIN-9, together with B-MYB, has a critical role in the activation of genes that are essential for progression into mitosis. PMID: 17159899
42. The repressor complex that Mip/LIN-9 forms with p107 takes functional precedence over the transcriptional activation linked to the Mip/LIN-9 and B-Myb interaction. PMID: 17563750
43. The expression of stable, hypophosphorylated B-MYB in neuroblastoma may promote cell survival and induce aggressive tumor growth. PMID: 17588787
44. Some B-MYB alleles might be associated with a reduced risk of developing neoplastic disease. PMID: 18026132
45. MYBL2 gene expression was significantly higher in colorectal cancer patients than in healthy volunteers. PMID: 19016757
46. Insight into the influence of B-Myb in human breast cancer, which is of potential clinical importance for determining disease risk and guiding treatment. PMID: 19043454
47. B-MYB fails to dissociate from LINC in p53 mutant cells, that this contributes to increased G(2)-M gene expression in response to DNA damage, and that B-MYB is required for recovery from the G(2) DNA damage checkpoint in p53-negative cells. PMID: 19383908

Show More

Hide All

HGNC: 7548

OMIM: 601415

KEGG: hsa:4605

STRING: 9606.ENSP00000217026

UniGene: Hs.179718